{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:49:57Z","timestamp":1794293397953,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science Research Program funded by Sinai Center for Thrombosis Research (SCTR) and Drug Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-025-05812-x","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T10:52:34Z","timestamp":1766919154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cangrelor in critically ill patients with cardiogenic shock or post-cardiac arrest undergoing percutaneous coronary intervention: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Hendrianus","family":"Hendrianus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Yeub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hwan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhwan","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kubica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"5812_CR1","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001309","volume":"151","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2025;151:e771-862. https:\/\/doi.org\/10.1161\/CIR.0000000000001309.","journal-title":"Circulation"},{"key":"5812_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2022.10.023","volume":"16","author":"D Capodanno","year":"2023","unstructured":"Capodanno D, Angiolillo DJ. Timing, selection, modulation, and duration of P2Y12 inhibitors for patients with acute coronary syndromes undergoing PCI. JACC Cardiovasc Interv. 2023;16:1\u201318. https:\/\/doi.org\/10.1016\/j.jcin.2022.10.023.","journal-title":"JACC Cardiovasc Interv"},{"key":"5812_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/0091270009344986","volume":"50","author":"WS Akers","year":"2010","unstructured":"Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50:27\u201335. https:\/\/doi.org\/10.1177\/0091270009344986.","journal-title":"J Clin Pharmacol"},{"key":"5812_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13054-014-0495-z","volume":"18","author":"T Kander","year":"2014","unstructured":"Kander T, Dankiewicz J, Friberg H, Sch\u00f6tt U. Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study. Crit Care. 2014;18:495. https:\/\/doi.org\/10.1186\/s13054-014-0495-z.","journal-title":"Crit Care"},{"key":"5812_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.5603\/CJ.a2022.0029","volume":"31","author":"J Umi\u0144ska","year":"2022","unstructured":"Umi\u0144ska J, Ratajczak J, Pstr\u0105gowski K, Buszko K, Nadolny K, Fabiszak T, et al. The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor. Cardiol J. 2022;31:472\u20138. https:\/\/doi.org\/10.5603\/CJ.a2022.0029.","journal-title":"Cardiol J"},{"key":"5812_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4244\/EIJV9I1A10","volume":"9","author":"J Iqbal","year":"2013","unstructured":"Iqbal J, Sumaya W, Tatman V, Parviz Y, Morton AC, Grech ED, et al. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention. 2013;9:62\u20139. https:\/\/doi.org\/10.4244\/EIJV9I1A10.","journal-title":"EuroIntervention"},{"key":"5812_CR7","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318\u201329. https:\/\/doi.org\/10.1056\/NEJMoa0908628.","journal-title":"N Engl J Med"},{"key":"5812_CR8","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330\u201341. https:\/\/doi.org\/10.1056\/NEJMoa0908629.","journal-title":"N Engl J Med"},{"key":"5812_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with Cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1300815.","journal-title":"N Engl J Med"},{"key":"5812_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jcin.2025.01.451","volume":"18","author":"OL Emilsson","year":"2025","unstructured":"Emilsson OL, Mohammad MA, Grimfj\u00e4rd P, Persson J, Santos-Pardo I, Erlinge D, et al. Cangrelor during percutaneous coronary\u00a0intervention in patients with cardiogenic shock or cardiac arrest. JACC Cardiovasc Interv. 2025;18:853\u201362. https:\/\/doi.org\/10.1016\/j.jcin.2025.01.451.","journal-title":"JACC Cardiovasc Interv"},{"key":"5812_CR11","volume-title":"DAPT-SHOCK-AMI: Dual antiplatelet therapy for shock patients with acute myocardial infarction \u2013 Cangrelor in cardiogenic shock","author":"Z Motovska","year":"2025","unstructured":"Motovska Z, Bhatt DL, Hlinomaz O, Geisler T, Montalescot G, Bartus S, et al. DAPT-SHOCK-AMI: Dual antiplatelet therapy for shock patients with acute myocardial infarction \u2013 Cangrelor in cardiogenic shock. ESC Congress: Madrid, Spain; 2025."},{"key":"5812_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"5812_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"5812_CR14","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"GA Wells","year":"2000","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000."},{"key":"5812_CR15","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123:2736\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449.","journal-title":"Circulation"},{"key":"5812_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13072121","author":"P Kordis","year":"2024","unstructured":"Kordis P, Berden J, Mikuz U, Noc M. Immediate platelet inhibition strategy for comatose out-of-hospital cardiac arrest survivors undergoing percutaneous coronary intervention and mild therapeutic hypothermia. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13072121.","journal-title":"J Clin Med"},{"key":"5812_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","volume":"137","author":"M Droppa","year":"2019","unstructured":"Droppa M, Vaduganathan M, Venkateswaran RV, Singh A, Szumita PM, Roberts RJ, et al. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: a global, multicenter, matched pair analysis with oral P2Y(12) inhibition from the IABP-SHOCK II trial. Resuscitation. 2019;137:205\u201312. https:\/\/doi.org\/10.1016\/j.resuscitation.2019.02.008.","journal-title":"Resuscitation"},{"key":"5812_CR18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ehjacc\/zuad041","volume":"12","author":"U Zeymer","year":"2023","unstructured":"Zeymer U, Lober C, Richter S, Olivier CB, Huber K, Haring B, et al. Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and\/or with cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2023;12:462\u20133. https:\/\/doi.org\/10.1093\/ehjacc\/zuad041.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"5812_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2025.01.105","volume":"18","author":"W Abusnina","year":"2025","unstructured":"Abusnina W, Chitturi KR, Verma BR, Chaturvedi A, Lupu L, Haberman D, et al. 100.25 impact of Cangrelor on patients with acute myocardial infarction-induced cardiogenic shock undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2025;18:S32. https:\/\/doi.org\/10.1016\/j.jcin.2025.01.105.","journal-title":"JACC Cardiovasc Interv"},{"key":"5812_CR20","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/aor.14590","volume":"47","author":"D Cohan","year":"2023","unstructured":"Cohan D, Uricchio MN, Konopka CI, Montepara CA, Verlinden NJ. Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual antiplatelet therapy in patients supported with venoarterial extracorporeal membrane oxygenation. Artif Organs. 2023;47:1672\u20137. https:\/\/doi.org\/10.1111\/aor.14590.","journal-title":"Artif Organs"},{"key":"5812_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.resuscitation.2018.06.032","volume":"130","author":"M Fiore","year":"2018","unstructured":"Fiore M, Gerbaud E, Coste P, Cetran L, Marchand H, Seguy B. Optimal platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention. Resuscitation. 2018;130:e1-2. https:\/\/doi.org\/10.1016\/j.resuscitation.2018.06.032.","journal-title":"Resuscitation"},{"key":"5812_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuaf082","author":"G Gelbenegger","year":"2025","unstructured":"Gelbenegger G, Lipa AJ, Jorda A, Zilberszac R, Heinz G, Staudinger T, et al. Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors. Eur Heart J Acute Cardiovasc Care. 2025. https:\/\/doi.org\/10.1093\/ehjacc\/zuaf082.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"5812_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110442","author":"F Pr\u00fcller","year":"2018","unstructured":"Pr\u00fcller F, Bis L, Milke OL, Fruhwald F, P\u00e4tzold S, Altmanninger-Sock S, et al. Cangrelor induces more potent platelet inhibition without increasing bleeding in resuscitated patients. J Clin Med. 2018. https:\/\/doi.org\/10.3390\/jcm7110442.","journal-title":"J Clin Med"},{"key":"5812_CR24","doi-asserted-by":"publisher","first-page":"B189","DOI":"10.1016\/j.jacc.2023.09.480","volume":"82","author":"Y Spahr","year":"2023","unstructured":"Spahr Y, Seiler T, Tersalvi G, Madanchi M, Cioffi GM, Zhi Y, et al. TCT-471 cangrelor in patients undergoing percutaneous coronary intervention with mechanical support devices: insights from a Swiss registry. J Am Coll Cardiol. 2023;82:B189\u2013B189. https:\/\/doi.org\/10.1016\/j.jacc.2023.09.480.","journal-title":"J Am Coll Cardiol"},{"key":"5812_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14010076","author":"M Ferlini","year":"2025","unstructured":"Ferlini M, Raone L, Bendotti S, Currao A, Primi R, Bongiorno A, et al. Cangrelor in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14010076.","journal-title":"J Clin Med"},{"key":"5812_CR26","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"5812_CR27","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1161\/01.CIR.0000162477.70955.5F","volume":"111","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042\u20139.","journal-title":"Circulation"},{"key":"5812_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00228-012-1360-0","volume":"69","author":"L Sou\u010dkov\u00e1","year":"2013","unstructured":"Sou\u010dkov\u00e1 L, Opat\u0159ilov\u00e1 R, Suk P, \u010cundrle I, Pavl\u00edk M, Zvon\u00ed\u010dek V, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69:309\u201317. https:\/\/doi.org\/10.1007\/s00228-012-1360-0.","journal-title":"Eur J Clin Pharmacol"},{"key":"5812_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022125","volume":"10","author":"L De Luca","year":"2021","unstructured":"De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Assoc. 2021;10:e022125. https:\/\/doi.org\/10.1161\/JAHA.121.022125.","journal-title":"J Am Heart Assoc"},{"key":"5812_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","volume":"62","author":"D Morales Castro","year":"2023","unstructured":"Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023;62:209\u201320. https:\/\/doi.org\/10.1007\/s40262-023-01213-x.","journal-title":"Clin Pharmacokinet"},{"key":"5812_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00392-016-1035-4","volume":"106","author":"S-Y Lee","year":"2017","unstructured":"Lee S-Y, Hong M-K, Shin D-H, Kim J-S, Kim B-K, Ko Y-G, et al. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol. 2017;106:165\u201373. https:\/\/doi.org\/10.1007\/s00392-016-1035-4.","journal-title":"Clin Res Cardiol"},{"key":"5812_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.758","author":"G De Luca","year":"2012","unstructured":"De Luca G, Dirksen MT, Spaulding C, Kelb\u00e6k H, Schalij M, Thuesen L, et al. Drug-Eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012. https:\/\/doi.org\/10.1001\/archinternmed.2012.758.","journal-title":"Arch Intern Med"},{"key":"5812_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.4244\/EIJ-D-22-00336","volume":"18","author":"M Rauber","year":"2022","unstructured":"Rauber M, Nicol P, Sabic E, Joner M, Noc M. Timing and predictors of definite stent thrombosis in comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention and therapeutic hypothermia (ST-OHCA study). EuroIntervention. 2022;18:740\u20138. https:\/\/doi.org\/10.4244\/EIJ-D-22-00336.","journal-title":"EuroIntervention"},{"key":"5812_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccc.2006.02.011","volume":"22","author":"BA Boucher","year":"2006","unstructured":"Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Pharmacotherapy. 2006;22:255\u201371. https:\/\/doi.org\/10.1016\/j.ccc.2006.02.011.","journal-title":"Pharmacotherapy"},{"key":"5812_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/1074248415571456","volume":"20","author":"PA Weeks","year":"2015","unstructured":"Weeks PA, Sieg A, Paruthi C, Rajapreyar I. Antiplatelet therapy considerations in ischemic cardiogenic shock: implications of metabolic bioactivation. J Cardiovasc Pharmacol Ther. 2015;20:370\u20137. https:\/\/doi.org\/10.1177\/1074248415571456.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"5812_CR36","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jcin.2020.02.042","volume":"13","author":"A Freund","year":"2020","unstructured":"Freund A, Jobs A, Lurz P, Feistritzer H-J, de Waha-Thiele S, Meyer-Saraei R, et al. Frequency and impact of bleeding on outcome in patients with cardiogenic shock. JACC Cardiovasc Interv. 2020;13:1182\u201393. https:\/\/doi.org\/10.1016\/j.jcin.2020.02.042.","journal-title":"JACC Cardiovasc Interv"},{"key":"5812_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","volume":"142","author":"G Gargiulo","year":"2020","unstructured":"Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G, et al. Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the fabolus-faster trial. Circulation. 2020;142:441\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046928.","journal-title":"Circulation"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05812-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:51:15Z","timestamp":1774360275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-025-05812-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5812"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05812-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7953604\/v1","asserted-by":"object"}]},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YHJ has received honoraria for lectures from Daiichi Sankyo, Sanofi-Aventis, Han-mi Pharmaceuticals, and Daewoong Pharmaceuticals and research grants or support from Samjin Pharmaceuticals, Hanmi Pharmaceuticals, Yuhan Pharmaceuticals, Biotronik Korea, and U and I Corporation. DAG reports institutional grants from AstraZeneca, and honoraria from BMS, Janssen and Chiesi. JK has been involved in the DAPT-SHOCK-AMI trial as an investigator and received personal fees from AstraZeneca, Ferrer, Adamed and Krka. PAG has received grants and personal fees from Bayer HealthCare, Otitopic, Amgen, and Janssen, US World-Meds; grants from Instrumentation Laboratory, Hikari Dx, Haemonetics, Medicure, and Idorsia Pharmaceuticals; and personal fees from UpToDate and has patents \u201cDetection of Restenosis Risk in Patients Issued\u201d and \u201cAssessment of Cardiac Health and Thrombotic Risk in a Patient.\u201d","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}